Arto Toivonen has been appointed as President of Fermion Oy, a subsidiary of Orion Corporation, effective January 1, 2015. Arto Toivonen has worked in Orion since 2006 in the Business Development and Alliance Management Department as a Business Development Director.
Before joining Orion Arto Toivonen worked for Juvantia Pharma Oy as the Vice President of Business Development and a member of Juvantia's management team during 2000-2006. During 1996-2000 he worked in Genencor International B.V. in Leiden, the Netherlands as a Key Account Manager and was responsible for sales of biotechnological products for global customers in several industries.
Arto has a Master of Science (Technology) degree in chemical engineering from the University of Technology in Espoo.
The current president of Fermion, M.Sc. (Tech.) Jorma Mamia (61) will continue as Corporate Security Director in Orion as of 1 January 2015. He has planned to retire in the end of 2015.
Contact person:
Liisa Hurme
Chairman of the Board of Fermion Oy
SVP, Specialty Products, Orion Corporation
Tel +358 50 966 2874
Photo of Arto Toivonen:
http://www.orion.fi/globalassets/pictures/orion-group/media/arto-toivonen.jpg
Published by:
Orion Corporation
Communications
Orionintie 1A, 02200 Espoo
www.orion.fi
Orion is a globally operating Finnish company that develops pharmaceuticals and diagnostic tests - a builder of well-being. It develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is constantly developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, cancer and critical care drugs and inhalable Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million, and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on NASDAQ OMX Helsinki.